Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Agents and Cancer
Published in: Infectious Agents and Cancer 1/2008

Open Access 01-12-2008 | Guidelines

Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention

Authors: Luisa Barzon, Colomba Giorgi, Franco M Buonaguro, Giorgio Palù, the Italian Society for Virology

Published in: Infectious Agents and Cancer | Issue 1/2008

Login to get access

Abstract

Objective

To provide guidelines for health-care providers on strategies for cervical cancer prevention based on HPV testing and anti-HPV vaccination.

Outcomes

Overall efficacy of different preventive strategies, assessing reduction in the incidence of invasive cervical cancer and precancerous lesions.

Evidence

Medline and the Cochrane Database were searched for articles in English on subjects related to HPVs, HPV diagnosis, HPV anogenital lesions, cervical cancer, HPV testing, and HPV vaccines, in order to elaborate an up-dated document. Relevant Italian Government publications and position papers from appropriate health and family planning organizations were also reviewed.

Values

The quality of the evidence and ranking of recommendations for practice were rated using criteria defined by SIV, which were adapted from the Canadian Task Force on Preventive Health Care.
Literature
1.
World Health Organization, International Agency for Research on Cancer: IARC Monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses. 2007, Lyon: IARC, 90:
2.
Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0. 2004, Lyon: IARC Press
3.
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors: Cancer incidence in five continents. 2002, Lyon: IARC Scientific Publications No. 155 IARC, III:
4.
Arbyn M, Autier P, Ferlay J: Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol. 2007, 18: 1425-1427. 10.1093/annonc/mdm398.
5.
I tumori in Italia – Rapporto 2006: Cervical cancer. e&p anno 30 gennaio-febbraio. 2006, suppl. 2
6.
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, editors: SEER Cancer Statistics Review, 1975–2002. 2005, Bethesda, MD: National Cancer Institute
7.
Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Möller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, EUROCARE Working Group: EUROCARE-3: survival of cancer patients diagnosed 1990–94 – results and commentary. Ann Oncol. 2003, 14 (Suppl. 5): v61-118. 10.1093/annonc/mdg754.PubMed
8.
Gondos A, Chokunonga E, Brenner H, Parkin DM, Sankila R, Borok MZ, Chirenje ZM, Nyakabau AM, Bassett MT: Cancer survival in southern African urban population. Int J Cancer. 2004, 112: 860-864. 10.1002/ijc.20471.PubMed
9.
zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW: Attempts to detect virus-specific DNA sequences in human tumors: I. Nucleic acid hybridization with complementary RNA of human wart virus. Int J Cancer. 1974, 13: 650-656. 10.1002/ijc.2910130509.PubMed
10.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology. 2004, 324: 17-27. 10.1016/j.virol.2004.03.033.PubMed
11.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641.PubMed
12.
Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: HPV in the etiology of human cancer. Vaccine. 2006, 24 (Suppl 3): S1-S10. 10.1016/j.vaccine.2006.05.115.
13.
Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL: HPV type distribution in women with and without cervical neoplastic diseases. Vaccine. 2006, 24 (Suppl 3): S26-34. 10.1016/j.vaccine.2006.05.026.
14.
Trottier H, Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine. 2006, 24 (Suppl 1): S1-S15.PubMed
15.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMed
16.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007, 121: 621-632. 10.1002/ijc.22527.PubMed
17.
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1157-1164. 10.1158/1055-9965.EPI-04-0812.PubMed
18.
de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007, 7: 453-459. 10.1016/S1473-3099(07)70158-5.PubMed
19.
Ronco G, Ghisetti V, Segnan N, Snijders PJ, Gillio-Tos A, Meijer CJ, Merletti F, Franceschi S: Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer. 2005, 41: 297-305. 10.1016/j.ejca.2004.07.005.PubMed
20.
Tornesello ML, Duraturo ML, Botti G, Greggi S, Piccoli R, De Palo G, Montella M, Buonaguro L, Buonaguro FM, Italian HPV Working Group: Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol. 2006, 78: 1663-1672. 10.1002/jmv.20752.PubMed
21.
Menzo S, Ciavattini A, Bagnarelli P, Marinelli K, Sisti S, Clementi M: Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiology. 2008, 8: 112-10.1186/1471-2180-8-112.PubMedPubMedCentral
22.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004, 111: 278-285. 10.1002/ijc.20244.PubMed
23.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N, New Technologies for Cervical Cancer Screening Working Group: Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008, 100: 492-501. 10.1093/jnci/djn065.PubMed
24.
Ammatuna P, Giovannelli L, Matranga D, Ciriminna S, Perino A: Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, South Italy. Cancer Epidemiol Biomarkers Prev. 2008, 17: 2002-2006. 10.1158/1055-9965.EPI-08-0180.PubMed
25.
Kiær SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T: Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer. 2008, 123: 1864-1870. 10.1002/ijc.23712.
26.
Prétet J-L, Jacquard A-C, Saunier M, Clavel C, Dachez R, Gondry J, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, for the EDiTH study group: Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer. The EDiTH III study. Gynecol Oncol. 2008, 110: 179-184. 10.1016/j.ygyno.2008.04.012.PubMed
27.
Pretet J-L, Jacquard A-C, Carcopino X, Monnier-Benoit S, Averous G, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, for the EDITH study group: Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer. 2008, 122: 424-427. 10.1002/ijc.23093.PubMed
28.
Pretet J-L, Jacquard A-C, Carcopino X, Charlot j-F, Bouhour D, Kantelip B, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, for the EDITH study group: Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer. 2008, 122: 428-432. 10.1002/ijc.23092.PubMed
29.
zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002, 2: 342-350. 10.1038/nrc798.PubMed
30.
D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007, 356: 1944-1956. 10.1056/NEJMoa065497.PubMed
31.
Tornesello ML, Duraturo ML, Losito S, Botti G, Pilotti S, Stefanon B, De Palo G, Gallo A, Buonaguro L, Buonaguro FM: Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer. 2008, 122: 132-137. 10.1002/ijc.23062.PubMed
32.
Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006, 110: 525-541. 10.1042/CS20050369.PubMed
33.
Howley PM, Lowy DR: Papillomaviruses. Fields Virology. Edited by: Knipe DM, Howley PM. 2007, Lippincott Williams & Wilkins Philadelphia, PA, USA, 5
34.
Liu JS, Kuo SR, Broker TR, Chow LT: The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication. J Biol Chem. 1995, 270: 27283-27291. 10.1074/jbc.270.45.27283.PubMed
35.
Spalholz BA, Yang YC, Howley PM: Transactivation of a bovine papillomavirus transcriptional regulatory element by the E2 gene product. Cell. 1985, 42: 183-191. 10.1016/S0092-8674(85)80114-8.PubMed
36.
Bernard BA, Bailly C, Lenoir MC, Darmon M, Thierry F, Yaniv M: The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J Virol. 1989, 63: 4317-4324.PubMedPubMedCentral
37.
Doorbar J, Ely S, Sterling J, McLean C, Crawford L: Specific interaction between HPV-16 E1–E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature. 1991, 352: 824-827. 10.1038/352824a0.PubMed
38.
Conrad M, Bubb Vj, Schleger R: The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol. 1993, 67: 6170-6178.PubMedPubMedCentral
39.
Straight SW, Herman B, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol. 1995, 69: 3185-3192.PubMedPubMedCentral
40.
Goodwin EC, Naeger LK, Breiding DE, Androphy EJ, DiMaio D: Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J Virol. 1998, 72: 3925-3934.PubMedPubMedCentral
41.
Münger K, Scheffner M, Huibregtse JM, Howley PM: Interaction of HPV E6 and E7 with tumor suppressor gene products. Cancer Surv. 1992, 12: 197-217.PubMed
42.
Dyson N, Howley PM, Münger K, Harlow E: The human papillomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science. 1989, 243: 934-937. 10.1126/science.2537532.PubMed
43.
Boyer SN, Wazer DE, Band V: E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56: 4620-4624.PubMed
44.
Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Dürr P: Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene. 1996, 13: 2323-2330.PubMed
45.
Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA: Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997, 11: 2090-2100. 10.1101/gad.11.16.2090.PubMedPubMedCentral
46.
Jones DL, Alani RM, Münger K: The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997, 11: 2101-2111. 10.1101/gad.11.16.2101.PubMedPubMedCentral
47.
Duensing S, Münger K: The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Proc Natl Acad Sci USA. 2000, 97: 10002-10007. 10.1073/pnas.170093297.PubMedPubMedCentral
48.
Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990, 248: 76-79. 10.1126/science.2157286.PubMed
49.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993, 75: 495-505. 10.1016/0092-8674(93)90384-3.PubMed
50.
Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985, 314: 111-114. 10.1038/314111a0.PubMed
51.
Jeon S, Lambert PF: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA. 1995, 92: 1654-1658. 10.1073/pnas.92.5.1654.PubMedPubMedCentral
52.
Kersemaekers AM, Vijver van de MJ, Kenter GG, Fleuren GJ: Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer. 1999, 26: 346-354. 10.1002/(SICI)1098-2264(199912)26:4<346::AID-GCC9>3.0.CO;2-D.PubMed
53.
Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C, American Cancer Society: American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002, 52: 342-362.PubMed
54.
Smith RA, Cokkinides V, Eyre HJ: Cancer screening in the United States, 2007: A review of current guidelines, practices, and prospects. CA Cancer J Clin. 2007, 57: 90-104.PubMed
55.
Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening test. Am J Obstet Gynecol. 2007, 197: 346-355. 10.1016/j.ajog.2007.07.047.PubMed
56.
Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007, 197: 340-345. 10.1016/j.ajog.2007.07.050.PubMed
57.
Council of the European Union: Council Recommendation of 2 December on Cancer Screening. Off J Eur Union. 2003, 878: 34-38.
58.
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener HG, Herbert A, Daniel J, von Karsa L: European guidelines for quality assurance in cervical cancer screening. 2008, Luxembourg: Office for Official Publications of the European Communities, Second
59.
Ministero della Salute, Direzione Generale della Prevenzione: Raccomandazioni per la pianificazione e l'esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro della cervice uterina e del cancro del colon retto. 2006
60.
Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000, 132: 810-819.PubMed
61.
Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J: Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004, 96: 280-293.PubMed
62.
Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006, 119: 1095-1101. 10.1002/ijc.21955.PubMed
63.
Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E: Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007, 104: 232-246. 10.1016/j.ygyno.2006.08.053.PubMed
64.
Stoler MH, Schiffman M, for the Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group: Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001, 285: 1500-1505. 10.1001/jama.285.11.1500.PubMed
65.
Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J: Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine. 2006, 24 (S3): 78-89. 10.1016/j.vaccine.2006.05.117.
66.
Taylor S, Kuhn L, Dupree W, Denny L, De Souza M, Wright TC: Direct comparison of liquid-based and conventional cytology in a south African screening trial. Int J Cancer. 2006, 118: 957-962. 10.1002/ijc.21434.PubMed
67.
Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M: Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007, 335: 28-10.1136/bmj.39196.740995.BE.PubMedPubMedCentral
68.
Solomon D, Schiffman M, Tarone R, ALTS Study group: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001, 93: 293-299. 10.1093/jnci/93.4.293.PubMed
69.
Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ, ALTS Group: Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst. 2006, 98: 92-100.PubMed
70.
Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J: Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol. 2005, 99 (Suppl 3): 7-11. 10.1016/j.ygyno.2005.07.033.
71.
ALTS group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000, 92: 397-402. 10.1093/jnci/92.5.397.
72.
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P, NTCC working group: HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer. 2007, 43: 476-480. 10.1016/j.ejca.2006.11.013.PubMed
73.
Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, Leroy JL: Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol. 2003, 90: 587-592. 10.1016/S0090-8258(03)00372-X.PubMed
74.
Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, Makrydimas G, Tofoski J, Roukos DH: The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004, 30: 205-211. 10.1016/j.ctrv.2003.07.008.PubMed
75.
Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler CM, Castle PE: Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev. 2006, 15: 908-914. 10.1158/1055-9965.EPI-05-0845.PubMed
76.
Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ: HPV testing and monitoring of women after treatment of CIN3: review of the literature and meta-analysis. Obstet Gynecol Surv. 2004, 59: 543-553. 10.1097/00006254-200407000-00024.PubMed
77.
Franco EL: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 2003, 31: 89-96.PubMed
78.
Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P: Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003, 362: 1871-1876. 10.1016/S0140-6736(03)14955-0.PubMed
79.
Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, Ronco G, Hakama M: A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer. 2006, 118: 791-796. 10.1002/ijc.21611.PubMed
80.
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J, New Technologies for Cervical Cancer Working Group: Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006, 98: 765-774.PubMed
81.
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J, New Technologies for Cervical Cancer screening Working Group: Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006, 7: 547-555. 10.1016/S1470-2045(06)70731-8.PubMed
82.
Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Lestani M, Onnis G, Aldovini D, Galanti G, Casadei G, Aldi M, Gomes V, Giubilato P, Ronco G, NTCC Pathology Group: The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol. 2008, 129: 75-80. 10.1309/EWYGWFRRM8798U5P.PubMed
83.
Bulkmans NWJ, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, Bulk S, Voorhorst FJ, Verheijen RHM, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJF, Meijer CJLM: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007, 370: 1764-1772. 10.1016/S0140-6736(07)61450-0.PubMed
84.
Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson B-G, Rylander E, Dillner J: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007, 357: 1589-1597. 10.1056/NEJMoa073204.PubMed
85.
Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003, 95: 46-52.PubMed
86.
Mayrand M-H, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, for the Canadian Cervical Cancer Screening Trial Study Group: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007, 357: 1579-1588. 10.1056/NEJMoa071430.PubMed
87.
Nobbenhuis MA, Helmerhorst TJ, Brule van den AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ: Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001, 358: 1782-1783. 10.1016/S0140-6736(01)06809-X.PubMed
88.
Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P: The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995, 61: 306-311. 10.1002/ijc.2910610305.PubMed
89.
Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995, 87: 1365-1371. 10.1093/jnci/87.18.1365.PubMed
90.
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998, 338: 423-428. 10.1056/NEJM199802123380703.PubMed
91.
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, Linden van der HC, Voorhorst FJ, Kenemans P, Meijer CJ: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999, 354: 20-25. 10.1016/S0140-6736(98)12490-X.PubMed
92.
Dalstein V, Riethmuller D, Prétet JL, Le Bail Carval K, Sautière JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C: Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003, 106: 396-403. 10.1002/ijc.11222.PubMed
93.
Gingelmaier A, Grubert T, Kaestner R, Mylonas I, Weissenbacher T, Bergauer F, Barthell L, Friese K: High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res. 2007, 27: 1795-1798.PubMed
94.
Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P, Clavel C: Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer. 2002, 102: 519-525. 10.1002/ijc.10735.PubMed
95.
Bais AG, Rebolj M, Snijders PJ, de Schipper FA, Meulen van der DA, Verheijen RH, Voorhorst F, van Ballegooijen M, Meijer CJ, Helmerhorst TJ: Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer. 2005, 116: 122-129. 10.1002/ijc.20958.PubMed
96.
Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005, 337: 76-84. 10.1016/j.virol.2005.04.002.PubMed
97.
Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H: Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006, 44: 1310-1317. 10.1128/JCM.44.4.1310-1317.2006.PubMedPubMedCentral
98.
Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B: Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev. 2005, 14: 367-372. 10.1158/1055-9965.EPI-04-0410.PubMed
99.
Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, Skomedal H, Thoresen SO, Hagmar B: Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer. 2005, 114: 973-976. 10.1002/ijc.20839.PubMed
100.
de Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB, Fleuren GJ: High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res. 2007, 13: 132-138. 10.1158/1078-0432.CCR-06-1568.PubMed
101.
Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, Holladay EB, Kolk DP: A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007, 13: 2599-2605. 10.1158/1078-0432.CCR-06-2881.PubMed
102.
Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB: Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet. 2000, 355: 2189-2193. 10.1016/S0140-6736(00)02401-6.PubMed
103.
Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, Adami HO, Gyllensten UB, Melbye M: Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000, 355: 2194-2198. 10.1016/S0140-6736(00)02402-8.PubMed
104.
Lo KW, Yeung SW, Cheung TH, Siu NS, Kahn T, Wong YF: Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: a study in Chinese population. J Clin Virol. 2005, 34: 76-80. 10.1016/j.jcv.2005.05.006.PubMed
105.
Moberg M, Gustavsson I, Wilander E, Gyllensten U: High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer. 2005, 92: 891-894. 10.1038/sj.bjc.6602436.PubMedPubMedCentral
106.
Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, Tristram AJ, Beukenholdt RW, Powell NG: Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J Med Virol. 2007, 79: 1366-1369. 10.1002/jmv.20875.PubMed
107.
Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M: Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002, 360: 228-229. 10.1016/S0140-6736(02)09463-1.PubMed
108.
Flores R, Papenfuss M, Klimecki WT, Giuliano AR: Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J Cancer. 2006, 118: 1187-1193. 10.1002/ijc.21477.PubMed
109.
Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker MC, Meijer CJ: Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer. 2006, 119: 1102-1107. 10.1002/ijc.21956.PubMed
110.
Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992, 327: 1272-1278.PubMed
111.
Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005, 97: 1072-1079.PubMed
112.
Castle PE, Solomon D, Schiffman M, Wheeler CM: Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005, 97: 1066-1071.PubMed
113.
Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006, 98: 303-315.PubMed
114.
Zuna RE, Allen RA, Moore WE, Lu Y, Mattu R, Dunn ST: Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol. 2007, 20: 167-174. 10.1038/modpathol.3800723.PubMed
115.
Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R, Zhang W: Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol. 2007, 20: 256-266. 10.1038/modpathol.3800737.PubMed
116.
Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A: Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 2001, 93: 1325-1330. 10.1093/jnci/93.17.1325.PubMed
117.
Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A, Bratti MC, Sherman ME, Scarpidis U, Lin QQ, Terai M, Bromley RL, Buetow K, Apple RJ, Burk RD: Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst. 2001, 93: 315-318. 10.1093/jnci/93.4.315.PubMed
118.
Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL: High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer. 2007, 120: 1763-1768. 10.1002/ijc.22481.PubMed
119.
Zehbe I, Wilander E, Delius H, Tommasino M: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 1998, 58: 829-833.PubMed
120.
Brady CS, Duggan-keen MF, Davidson JA, Varley JM, Stern PL: Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J Gen Virol. 1999, 80: 3233-3240.PubMed
121.
Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S: Human papillomavirus Type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by Notch signaling and oncogenic ras. J Virol. 2004, 78: 5934-5945. 10.1128/JVI.78.11.5934-5945.2004.PubMedPubMedCentral
122.
Watts KJ, Thompson CH, Cossart YE, Rose BR: Variable oncogene promoter activity of human papillomavirus type 16 cervical cancer isolates from Australia. J Clin Microbiol. 2001, 39: 2009-2014. 10.1128/JCM.39.5.2009-2014.2001.PubMedPubMedCentral
123.
Watts KJ, Thompson CH, Cossart YE, Rose BR: Sequence variation and physical state of human papillomavirus type 16 cervical cancer isolates from Australia and New Caledonia. Int J Cancer. 2002, 97: 868-874. 10.1002/ijc.10103.PubMed
124.
Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD, PEG Group; ALTS Group: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005, 97: 147-50.PubMed
125.
Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J: HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007, 97: 129-132. 10.1038/sj.bjc.6603843.PubMedPubMedCentral
126.
Vernon SD, Unger ER, Miller DL, Lee DR, Reeves WC: Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int J Cancer. 1997, 74: 50-56. 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.0.CO;2-#.PubMed
127.
Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B, Johansson B: Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol. 1998, 17: 146-153.PubMed
128.
Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel DM: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001, 92: 276-284. 10.1002/ijc.1174.PubMed
129.
Mao C, Balasubramanian A, Yu M, Kiviat N, Ridder R, Reichert A, Herkert M, von Knebel Doeberitz M, Koutsky LA: Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer. 2007, 120: 2435-2438. 10.1002/ijc.22612.PubMed
130.
Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, Burk RD, Hildesheim A, Bratti MC, Wright T, Rodriguez AC, Chen S, Reichert A, von Knebel Doeberitz C, Ridder R, von Knebel Doeberitz M: Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1355-1360.PubMed
131.
Holladay EB, Logan S, Arnold J, Knesel B, Smith GD: A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer. 2006, 108: 451-461. 10.1002/cncr.22284.PubMed
132.
Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel DM: p16INK4A immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002, 26: 1389-1399. 10.1097/00000478-200211000-00001.PubMed
133.
Carozzi F, Confortini M, Palma PD, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, Ronco G, the New Technologies for Cervival Cancer screening (NTCC) working group: Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9 (10): 937-945. 10.1016/S1470-2045(08)70208-0.
134.
Ho GY, Studentsov YY, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002, 186: 737-742. 10.1086/342972.PubMed
135.
Ho GY, Studentsov YY, Bierman R, Burk RD: Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev. 2004, 13: 110-116. 10.1158/1055-9965.EPI-03-0191.PubMed
136.
Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller JT, Hakulinen T, Thoresen S, Hakama M: Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst. 1997, 89: 1293-1299. 10.1093/jnci/89.17.1293.PubMed
137.
Einstein MH, Studentsov YY, Ho GY, Fazzari M, Marks M, Kadish AS, Goldberg GL, Runowicz CD, Burk RD: Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. Int J Cancer. 2006, 120: 55-59. 10.1002/ijc.22176.
138.
Iftner T, Villa LL: Human papillomavirus technologies. J Natl Cancer Inst Monogr. 2003, 31: 80-88.PubMed
139.
Rizk RZ, Christensen ND, Michael KM, Müller M, Sehr P, Waterboer T, Pawlita M: Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol. 2008, 89: 117-129. 10.1099/vir.0.83145-0.PubMed
140.
de Jong A, van Poelgeest MI, Hulst van der JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, Burg van der SH: Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004, 64: 5449-5455. 10.1158/0008-5472.CAN-04-0831.PubMed
141.
Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, Hulst van der JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, Burg van der SH: High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67: 354-361. 10.1158/0008-5472.CAN-06-3388.PubMed
142.
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Proof of Principle Study Investigators: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002, 347: 1645-1651. 10.1056/NEJMoa020586.PubMed
143.
Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006, 107: 18-27.PubMed
144.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human Papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364: 1757-1765. 10.1016/S0140-6736(04)17398-4.PubMed
145.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006, 367: 1247-1255. 10.1016/S0140-6736(06)68439-0.PubMed
146.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA study group: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007, 369: 2161-2170. 10.1016/S0140-6736(07)60946-5.PubMed
147.
Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup. Br J Cancer. 2006, 95: 1459-1466. 10.1038/sj.bjc.6603469.PubMedPubMedCentral
148.
FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007, 356: 1915-1927. 10.1056/NEJMoa061741.
149.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007, 356: 1928-1943. 10.1056/NEJMoa061760.PubMed
150.
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006, 24: 5937-5949. 10.1016/j.vaccine.2006.06.005.PubMed
151.
Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G, HPV Vaccine Adolescent Study Investigators Network: Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007, 40: 564-571. 10.1016/j.jadohealth.2007.02.015.PubMed
152.
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6: 271-278. 10.1016/S1470-2045(05)70101-7.PubMed
153.
Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007, 25: 4931-4939. 10.1016/j.vaccine.2007.03.049.PubMed
154.
Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Reisinger KS, Protocol 016 Study Group: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006, 118: 2135-2145. 10.1542/peds.2006-0461.PubMed
155.
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E: Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007, 26: 201-209. 10.1097/01.inf.0000253970.29190.5a.PubMed
156.
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007, 369: 1693-1702. 10.1016/S0140-6736(07)60777-6.PubMed
157.
Ault KA, Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007, 369: 1861-1868. 10.1016/S0140-6736(07)60852-6.PubMed
158.
Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzales P, Dubin G, Porras C, Jimenez SE, Lowy DR, for the Costa Rican HPV Vaccine Trial Group: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA. 2007, 298: 743-753. 10.1001/jama.298.7.743.PubMed
159.
FUTURE II Study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007, 196: 1438-1446. 10.1086/522864.
160.
Jenkins D: A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008, 110: S18-S25. 10.1016/j.ygyno.2008.06.027.PubMed
161.
Barr E, Sings HL: Prophylactic HPV vaccines: New interventions for cancer control. Vaccine. 2008, 26: 6244-6257. 10.1016/j.vaccine.2008.07.056.PubMed
Metadata
Title
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention
Authors
Luisa Barzon
Colomba Giorgi
Franco M Buonaguro
Giorgio Palù
the Italian Society for Virology
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2008
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/1750-9378-3-14

Other articles of this Issue 1/2008

Infectious Agents and Cancer 1/2008 Go to the issue

Research article

Human papillomavirus (HPV) infection and intraepithelial neoplasia and invasive cancer of the uterine cervix: a case-control study in Zaragoza, Spain

Research article

Human herpesvirus-8 (HHV-8) sero-detection and HIV association in Kaposi's sarcoma (KS), non-KS tumors and non-neoplastic conditions

Research article

Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens

Research article

Characterisation of human papillomavirus (HPV) genotypes in the Azorean population, Terceira island

Review

Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma

Review

The Rho-activating CNF1 toxin from pathogenic E. coli: A risk factor for human cancer development?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits